Purpose
This retrospective study aimed to develop and validate an Ultrasound (US)‐based nomogram to predict short disease‐free survival (short‐DFS, less than 120 months DFS) in breast cancer (BC).
Methods
Nomogram was established based on a training data of 311 BC patients by multivariable logistic regression, and were assessed by discrimination, calibration, and clinical usefulness. Risk stratification was performed by X‐tile. An independent testing data of 200 patients with BC was used for external validation.
Results
Nine predictors including three US features and six clinical parameters were screened into the nomogram by Lasso (log λ = −3.594) in training data. Better performance was obtained in the training data (C‐index: 0.942) and testing data (C‐index: 0.914). Calibration analysis indicated optimal agreement between nomogram predictions and actual observations (p = 0.67). Decision curve analysis showed a great clinical benefit (Youden index: 0.634). Three risk levels are low‐risk (<184.0), moderate‐risk (184.0–345.3) and high‐risk (>345.3). Our nomograms had larger area under the receiver operating characteristic (ROC) curves compared with Magee Equation and Nottingham Prognostic models (0.942 vs. 0.824, 0.790).
Conclusion
The US‐based nomogram and the practical score system facilitate individualized prediction of short‐DFS to optimize clinical decisions and improve prognosis in patients with BC.